190 related articles for article (PubMed ID: 36525936)
21. ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer.
Zhang Z; Feng L; Liu P; Duan W
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30279206
[TBL] [Abstract][Full Text] [Related]
22. GRIM-19 inhibits proliferation and induces apoptosis in a p53-dependent manner in colorectal cancer cells through the SIRT7/PCAF/MDM2 axis.
Wang D; Wei X; Chen X; Wang Q; Zhang J; Kalvakolanu DV; Guo B; Zhang L
Exp Cell Res; 2021 Oct; 407(1):112799. PubMed ID: 34461110
[TBL] [Abstract][Full Text] [Related]
23. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
Wang Z; Zhan Y; Xu J; Wang Y; Sun M; Chen J; Liang T; Wu L; Xu K
J Agric Food Chem; 2020 Mar; 68(12):3850-3858. PubMed ID: 32167760
[TBL] [Abstract][Full Text] [Related]
24. Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.
Zhang B; Chan SH; Liu XQ; Shi YY; Dong ZX; Shao XR; Zheng LY; Mai ZY; Fang TL; Deng LZ; Zhou DS; Chen SN; Li M; Zhang XD
J Cell Mol Med; 2021 Sep; 25(18):8836-8849. PubMed ID: 34378321
[TBL] [Abstract][Full Text] [Related]
25. A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer.
Kendzia S; Franke S; Kröhler T; Golob-Schwarzl N; Schweiger C; Toeglhofer AM; Skofler C; Uranitsch S; El-Heliebi A; Fuchs J; Punschart A; Stiegler P; Keil M; Hoffmann J; Henderson D; Lehrach H; Yaspo ML; Reinhard C; Schäfer R; Keilholz U; Regenbrecht C; Schicho R; Fickert P; Lax SF; Erdmann F; Schulz MH; Kiemer AK; Haybaeck J; Kessler SM
Mol Cancer; 2023 May; 22(1):89. PubMed ID: 37248468
[TBL] [Abstract][Full Text] [Related]
26. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of CPT2 promotes proliferation and inhibits apoptosis through p53 pathway in colorectal cancer.
Liu F; Li X; Yan H; Wu J; Yang Y; He J; Chen J; Jiang Z; Wu F; Jiang Z
Cell Signal; 2022 Apr; 92():110267. PubMed ID: 35108639
[TBL] [Abstract][Full Text] [Related]
28. miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
Lv L; Li Q; Chen S; Zhang X; Tao X; Tang X; Wang S; Che G; Yu Y; He L
Exp Cell Res; 2019 Dec; 385(1):111597. PubMed ID: 31525340
[TBL] [Abstract][Full Text] [Related]
29. Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer.
Yang Y; Yuan H; Zhao L; Guo S; Hu S; Tian M; Nie Y; Yu J; Zhou C; Niu J; Wang G; Song Y
Cell Death Differ; 2022 Nov; 29(11):2177-2189. PubMed ID: 35484333
[TBL] [Abstract][Full Text] [Related]
30. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.
Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q
Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151
[TBL] [Abstract][Full Text] [Related]
31. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
[TBL] [Abstract][Full Text] [Related]
32. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
33. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
[TBL] [Abstract][Full Text] [Related]
34. ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy.
Zhao L; Chen H; Zhang Q; Ma J; Hu H; Xu L
Cancer Chemother Pharmacol; 2022 May; 89(5):595-607. PubMed ID: 35312836
[TBL] [Abstract][Full Text] [Related]
35. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
37. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
38. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
Cai J; Su L; Luo W
Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
[TBL] [Abstract][Full Text] [Related]
39. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.
Yu Z; Deng P; Chen Y; Liu S; Chen J; Yang Z; Chen J; Fan X; Wang P; Cai Z; Wang Y; Hu P; Lin D; Xiao R; Zou Y; Huang Y; Yu Q; Lan P; Tan J; Wu X
Adv Sci (Weinh); 2021 Dec; 8(23):e2100759. PubMed ID: 34881526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
